Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 355 points (-2.0%) at 17,323 as of Tuesday, Jan. 27, 2015, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,116 issues advancing vs. 1,852 declining with 163 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is down 1.4%. On the negative front, top decliners within the sector include Regeneron Pharmaceuticals ( REGN), down 1.6%, Becton Dickinson ( BDX), down 1.4%, Express Scripts ( ESRX), down 1.1%, Abbott Laboratories ( ABT), down 1.1% and Thermo Fisher Scientific ( TMO), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Waters ( WAT) is one of the companies pushing the Health Care sector higher today. As of noon trading, Waters is up $3.93 (3.4%) to $120.04 on heavy volume. Thus far, 577,765 shares of Waters exchanged hands as compared to its average daily volume of 433,100 shares. The stock has ranged in price between $116.51-$122.80 after having opened the day at $116.51 as compared to the previous trading day's close of $116.11.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. Waters has a market cap of $9.5 billion and is part of the health services industry. Shares are up 3.0% year-to-date as of the close of trading on Monday. Currently there are 3 analysts who rate Waters a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Waters as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Waters Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, AstraZeneca ( AZN) is up $1.31 (1.9%) to $71.88 on heavy volume. Thus far, 3.0 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $71.26-$72.22 after having opened the day at $71.52 as compared to the previous trading day's close of $70.57.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $89.3 billion and is part of the drugs industry. Shares are up 0.3% year-to-date as of the close of trading on Monday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates AstraZeneca as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Novartis ( NVS) is up $2.03 (2.1%) to $98.52 on heavy volume. Thus far, 2.0 million shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $98.01-$98.80 after having opened the day at $98.49 as compared to the previous trading day's close of $96.49.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $234.3 billion and is part of the drugs industry. Shares are up 4.1% year-to-date as of the close of trading on Monday. Currently there are 5 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null